A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease by Salloway S, Sperling R, Gilman S, Fox N C, Blennow K, Raskind M, Sabbagh M, Honig L S, Doody R, van Dyck C H, Mulnard R, Barakos J, Gregg K M, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators in Neurology (2009). PubMed

Abstract

Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.

[ hide abstract ]

Discussed In Paper